Geneoscopy's RNA-Based ColoSense Test Included in Latest National Comprehensive Cancer Network (NCCN) Guidelines
ST. LOUIS--(BUSINESS WIRE)--Jun 3, 2025--
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that its ColoSense® test has been included in the National Comprehensive Cancer Network® (NCCN) Guidelines for Colorectal Cancer (CRC) Screening as a first-line test for average-risk patients, supporting its role as a screening alternative for individuals aged 45 years and older. ColoSense is a noninvasive stool-based test for detecting CRC and advanced adenomas, and is the only FDA-approved screening test utilizing stool RNA biomarkers, which are not subject to age-related methylation. 1,2
The NCCN Guidelines are comprehensive, evidence-based recommendations to support the prevention, diagnosis, and treatment of more than 97% of cancers affecting patients in the United States. They are regularly updated to reflect the latest scientific evidence and improve the quality and consistency of cancer care.
'The NCCN Guidelines are among the most trusted clinical resources in oncology, and the addition of ColoSense is a powerful validation of its clinical performance,' said Erica Barnell, M.D., Ph.D., Chief Science and Medical Officer of Geneoscopy. 'As the first and only FDA-approved stool RNA screening test for colorectal cancer, this affirms the scientific rigor behind our technology and reinforces the importance of noninvasive modalities in expanding access and improving screening compliance, especially among populations less likely to undergo colonoscopy.'
ColoSense's inclusion in the NCCN Guidelines is based on data from Geneoscopy's CRC-PREVENT pivotal study, which was published in the Journal of the American Medical Association (JAMA). 3 Unlike traditional centralized trials, in which patients are typically already engaged in healthcare screening programs, nearly two-thirds of CRC-PREVENT participants had never undergone CRC screening or scheduled a colonoscopy at the time of enrollment. The study demonstrated ColoSense's ability to detect CRC with 94% sensitivity, identifying 100% of CRC in Stage I. Additionally, ColoSense detected 46% of advanced adenomas, when the disease is most preventable.
'The NCCN Guidelines heavily impact both the clinical adoption and insurance coverage of screening tests,' said Matt Sargent, Chief Commercial Officer of Geneoscopy. 'Achieving this milestone as a first-line test marks a pivotal step forward in our mission to bring ColoSense to market as an accurate, accessible screening solution for millions of Americans. NCCN guideline inclusion also positions ColoSense for future inclusion in other major guidelines.'
About ColoSense
ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.
A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA) in October 2023. For more information, visit www.colosense.com.
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
References
View source version on businesswire.com:https://www.businesswire.com/news/home/20250603217642/en/
CONTACT: Media Contact
Andrea Sampson
Sampson Public Relations Group
[email protected]
KEYWORD: MISSOURI UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH MANAGED CARE ONCOLOGY HEALTH GENETICS
SOURCE: Geneoscopy, Inc.
Copyright Business Wire 2025.
PUB: 06/03/2025 07:50 AM/DISC: 06/03/2025 07:50 AM
http://www.businesswire.com/news/home/20250603217642/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
NK Retail Partners with NuORDER by Lightspeed to Digitize Buying Process, Improve Customer Experience
NuORDER platform enables NK Retail to streamline back-end processes and decision-making, freeing time for greater focus on customers in stores MONTREAL, June 05, 2025--(BUSINESS WIRE)--NuORDER by Lightspeed, a leading B2B commerce platform powering wholesale buying and selling, has been selected by NK Retail, operating within NK, a world-class department store and one of Scandinavia's leading luxury destinations for fashion, beauty and design inspiration, as its strategic partner for retail transformation by digitizing its merchandising and buying process. Utilizing the NuORDER platform will enable NK Retail to drive efficiency and agility, allowing its teams to focus on delivering premium, service-first in-store experiences. As global markets create uncertainties for retailers, NuORDER by Lightspeed is a critical tool for retailers to make strategic buying and assortment planning decisions based on real-time data. NuORDER Assortments enables buyers to write orders 60% faster by eliminating pain points and manual processes when working with their brands. It also provides robust reporting and analytic capabilities to allow buyers and their brands to make data-driven buying decisions, yielding improved storytelling and merchandising experiences for customers in-store. "At NK Retail, delivering exceptional in-store service is at the heart of everything we do. By partnering with NuORDER, our buyers can work more efficiently and make better decisions, which in turn empowers our sales advisors to better serve our customers in the moment," said Karin Edgren, Buying Manager for NK Retail. "NuORDER streamlines how information flows across our teams, helping us uphold our commitment to offering the best in-store experience on the Swedish market." "We are observing a growing demand from retailers in the Nordic region for solutions that allow them to make data-driven decisions more quickly. This reflects their commitment to leading the way in digitization while supporting their sustainability goals and providing exceptional customer service," said Chris Akrimi, Head of Revenue for NuORDER by Lightspeed. "Our team is eager to assist NK Retail in its mission to streamline buying processes, ensuring a customer-centric approach by delivering a best-in-class in-store experience." NuORDER by Lightspeed powers leading and up-and-coming brands and retailers, including: Saks Fifth Avenue, Macy's, Nordstrom, Brunello Cucinelli, Rag & Bone, Acne Studios, Filippa K, and Samsøe Samsøe. About NuORDER by Lightspeed NuORDER by Lightspeed is a leading B2B commerce platform powering wholesale buying and selling. NuORDER offers a full suite of commerce solutions engineered to streamline the way brands sell their products all around the world while providing retailers with the insights they need to make better buying and assortment planning decisions. Today, more than 5,000 brands and more than 150,000 vetted retailers use NuORDER to transform their wholesale operations. Lightspeed acquired NuORDER in 2021. Powering the businesses that are the backbone of the global economy, Lightspeed's one-stop commerce platform helps merchants innovate to simplify, scale, and provide exceptional customer experiences. Lightspeed's cloud commerce solution transforms and unifies online and physical operations, multichannel sales, expansion to new locations, global payments, financial solutions, and connection to supplier networks. Founded in Montréal, Canada in 2005, Lightspeed is dual-listed on the New York Stock Exchange (NYSE: LSPD) and Toronto Stock Exchange (TSX: LSPD). With teams across North America, Europe, and Asia Pacific, the company serves retail, hospitality, and golf businesses in over 100 countries. Follow NuORDER on social media: LinkedIn, Facebook, Instagram, and X. Forward-Looking Statements This news release may include forward-looking information and forward-looking statements within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are predictive in nature, depend upon or refer to future events or conditions and are identified by words such as "will", "expects", "anticipates", "intends", "plans", "believes", "estimates" or similar expressions concerning matters that are not historical facts. Such statements are based on current expectations of Lightspeed's management and inherently involve numerous risks and uncertainties, known and unknown, including economic factors. A number of risks, uncertainties and other factors may cause actual results to differ materially from the forward-looking statements contained in this news release, including, among other factors, those risk factors identified in our most recent Management's Discussion and Analysis of Financial Condition and Results of Operations, under "Risk Factors" in our most recent Annual Information Form, and in our other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR+ at and on EDGAR at Readers are cautioned to consider these and other factors carefully when making decisions with respect to Lightspeed's subordinate voting shares and not to place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are not guarantees of future performance and, while forward-looking statements are based on certain assumptions that Lightspeed considers reasonable, actual events and results could differ materially from those expressed or implied by forward-looking statements made by Lightspeed. Except as may be expressly required by applicable law, Lightspeed does not undertake any obligation to update publicly or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts For further information: NuORDER by Lightspeed Media RelationsLaura Baumgartner, VP, Asylum Public Relationslbaumgartner@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Hospital needs help identifying 2 patients found injured in Los Angeles County
A Los Angeles County hospital needs help identifying two patients who were found injured. Both were found in Los Angeles County and were taken to the St. Francis Medical Center in Lynwood. The first patient is a woman around 68 years old. She was found at a bus stop at Pacific Avenue and Slauson Boulevard in Huntington Park. Hospital staff said she appears to be Hispanic and stands 5 feet 5 inches tall, weighs 200 pounds, has green eyes and auburn-brown dyed hair. She is unable to communicate her name or the names of her family members. She may have a son named George. The second patient is a man around 60 years old. His first name may be Miguel. He was brought to the hospital from a senior living facility in Bell Gardens. He appears to be Hispanic and is around 5 feet 7 inches tall and 134 pounds. He has brown eyes and black hair with graying temples. He is unable to communicate his name or the names of his family, staff said. Neither patient has any personal belongings to help workers identify them. Hospital staff did not disclose the nature of their injuries. Anyone who recognizes the patients is urged to call the hospital at 310-900-2094. For the woman, callers are asked to reference the name 'Irene,' and for the man, reference the name 'Miguel.' 'As with every patient, we hope to connect him to loved ones soon,' hospital officials said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Jamie Metzl and Steven Yates on China, national security threats
(NewsNation) — A Chinese scientist was arrested for allegedly trying to smuggle a dangerous fungus into the country. Author Jamie Metzl and Steven Yates with conservative think tank The Heritage Foundation say China is not taken as a serious threat by the U.S. and it should be. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
